Sarah Cannon and Lyell partner on cancer T-Cell therapy development

28th August 2020 (Last Updated August 28th, 2020 17:25)

Lyell Immunopharma and Sarah Cannon, both based in the US, have formed a strategic partnership to develop and clinically evaluate oncology-focused T-cell therapies.

Sarah Cannon and Lyell partner on cancer T-Cell therapy development
Life cycle of a cancer cell. Credit: BruceBlaus.

Lyell Immunopharma and Sarah Cannon, both based in the US, have formed a strategic partnership to develop and clinically evaluate oncology-focused T-cell therapies.

This partnership combines Lyell’s research and development (R&D) of cell-based immunotherapies and Sarah Cannon’s designing and optimising expertise in clinical trials to expand treatment options for patients.

Sarah Cannon is a clinical research organisation that conducts ‘community-based’ clinical trials throughout the US and UK.

The company’s ‘Blood Cancer Network’ is one of the largest providers of hematopoietic cell transplants. This network enables patients to have access to complex blood cancer care, including clinical trials and CAR T-Cell therapy.

Sarah Cannon president and chief medical officer Howard A Burris said: “We look forward to partnering with Lyell Immunopharma to accelerate development and access to innovative T-Cell therapies for patients who could potentially benefit from these treatment options.

“By bringing together Lyell Immunopharma’s scientific expertise with Sarah Cannon’s experience and expansive network, we can pursue an innovative approach to bring these cutting-edge treatment options into the community more rapidly and affordably for patients.”

Meanwhile, Lyell Immunopharma is a cellular therapy company focused on mastering immune cell functionality by advancing the science of T-Cell differentiation, functionality, as well as a specificity for developing ‘curative treatments’.

T-Cell therapies are currently being used for treating many forms of blood cancers, while CAR T-Cell therapies are approved for treating acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).

These therapies are also approved for hundreds of additional trials related to blood cancer and other solid tumours.

Lyell chief medical officer Tina Albertson said: “Lyell is very excited to be partnered with Sarah Cannon.

“This collaboration should result in the ability to more rapidly and efficiently initiate clinical trials and thus bring Lyell’s innovative cell therapy treatments to patients more quickly once trials are authorised to commence.”